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ABSTRACT
For pregnant women with high viral load, antiviral therapy has been administered 
in addition to active and passive immune prophylaxis as a crucial adjunctive therapy to 
interrupt mother-to-child hepatitis B virus (HBV) transmission (MTCT). However, the time 
of antiviral therapy onset remains controversial. A systematic review and meta-analysis was 
conducted to compare the efficacy of antiviral therapy during the second or the third trimester 
for prevention of HBV vertical transmission. We searched nine databases for observational 
studies and randomized controlled trials that enrolled pregnant women with positive HBsAg 
treated with antivirals. The outcomes of interest were maternal HBV-DNA levels prior to 
delivery and the rates of HBV MTCT. We included nine studies that enrolled 1,502 pregnant 
women. The average HBV-DNA level before treatment was approximately 8 log10 copies/
mL. Compared to the onset of antiviral intervention in the third trimester, the beginning of 
treatment in the second trimester distinctly reduced maternal predelivery HBV-DNA levels. 
However, no significant difference in HBV MTCT was found between the second and third 
trimester groups. Furthermore, the subgroup analysis showed that there were no significant 
differences between groups beginning treatment at different times (second or third trimester) 
with regard to HBV MTCT or other evaluated endpoints. For pregnant women with HBV-
DNA levels less than or equal to 8 log10 copies/mL, the beginning of antiviral treatment can 
be delayed until the third trimester.
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INTRODUCTION
Chronic hepatitis B (CHB) remains a serious global public health issue1-5. 
According to data from the World Health Organization (WHO), an estimated 
257 million people are infected with hepatitis B virus (HBV)3. Mother-to-child 
transmission (MTCT) is the major cause of CHB infection3,6,7. Prevention of HBV 
MTCT could therefore reduce the number of new HBV carriers. In addition, if 
HBV is left untreated, the risk of chronicity will depend on the age at which the 
patient acquired the infection (80-90% in newborns and< 5% in adults)8. Compared 
to the acute hepatitis B infection, CHB is more likely to result in severe long-term 
life-threatening complications, including cirrhosis and hepatocellular carcinoma. 
In 2015, 887,000 deaths were reported and attributed to HBV complications9. 
Therefore, preventing MTCT could effectively decrease deaths related to CHB.
Recently, infants have been subjected to active and passive immune prophylactic 
measures, called timely HepB-BD, and the WHO recommends completion of the HBV 
vaccine schedule as a mainstream procedure to prevent HBV vertical transmission6. 
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However, 5-10% of newborns are still infected by their 
HBV-positive mothers4,10. Infants born to mothers with 
high viral load (more than 106 copies/mL) and hepatitis 
B envelope antigen (HBeAg) positivity showed 10-30% 
immune prophylaxis failure, while those born to mothers with 
low maternal viral load (less than 106 copies/mL) show less 
than 3% failure8,10. Thus, antiviral intervention for pregnant 
women with high maternal HBV-DNA levels will help to 
achieve a global eradication of CHB infection10-12.
Although a consensus on the use of antiviral drugs to 
interrupt HBV MTCT has been reached, the proper timing of 
antiviral treatment during pregnancy remains controversial. 
Antiviral therapy is typically administered in the second and 
third trimesters of gestation. According to the American 
Association for the Study of Liver Diseases (AASLD)13 
and the Asian Pacific Association for the Study of the 
Liver (APASL)14, the starting point for maternal treatment 
should be at 28-32 weeks of gestation. The European 
Association for the Study of the Liver (EASL)15 and the 
Chinese Medical Association15,16 recommend treatment 
initiation at 24-28 weeks of gestation. However, related 
cohort studies with large sample sizes and randomized 
controlled trials (RCTs) are still lacking. Therefore, a 
systematic review and meta-analysis was conducted 
to compare the efficacy of antiviral therapy for HBV 
MTCT prevention in the second or in the third trimester.
METHODS
Search strategy
A comprehensive search of PubMed, Embase, the 
Cochrane Library, Ovid MEDLINE, Web of Science, 
SinoMed, the China National Knowledge Infrastructure 
(CNKI), the China Science and Technology Journal 
Database and the Wanfang Database was conducted 
from January 2013 to December 2018. The following 
search terms and their variations were used: “pregnant or 
mother”, “hepatitis B virus or HBV or chronic hepatitis B 
or CHB”, “antiviral or lamivudine or LAM or telbivudine 
or LdT or tenofovir or TDF”, “mother-to-child or MTCT 
or vertical or mother-to-fetus or maternal-neonatal” and 
“infection or transmission or prevention or control”. 
No language restrictions were applied. The reference 
lists were reviewed to identify additional articles.
Eligibility criteria
Studies were included if they met the following 
inclusion criteria: 1) they were RCTs or cohort studies; 
2) they included pregnant women with HBV infections who 
had accepted antiviral therapy during pregnancy; 3) they 
included only infants who received one dose of HBIG at 
birth and three doses of hepatitis B vaccine at birth or after 
delivery and 4) they included data on the MTCT rate. 
MTCT was considered to have occurred if HBsAg 
positivity was observed or if HBV-DNA levels were 
detectable when the infants were seven to 12 months old.
The following types of studies were excluded: 1) case 
reports, review articles, letters to the editor, editorials and 
conference abstracts; 2) studies in which patients were 
coinfected with HIV, HCV or HDV, or patients were not 
pregnant women; 3) studies in which patients received a 
combined-HBIG injection during pregnancy or 4) studies 
in which antiviral therapy was initiated before pregnancy 
or during early pregnancy (before the second trimester).
Data extraction
Two independent investigators examined the titles and 
abstracts. The full-text versions of the included articles 
were then reviewed, following the same procedure. 
Disagreements were reconciled by a third person. The 
following information was extracted from each study: 
authorship, publication year, the age of subjects (years), 
maternal HBV-DNA levels before antiviral intervention 
and prior to delivery, baseline ALT level, intervention and 
control subject numbers, the time of treatment onset (in 
gestational weeks), the time of treatment discontinuation (in 
postpartum weeks), the study design and MTCT rates. In the 
included trials, the second trimester referred to 13-27 weeks 
of gestation, while the third trimester referred to the period 
beginning at 28 weeks of gestation. The specific weeks of 
gestation during which antiviral therapy was initiated and 
the average duration of antiviral treatment were obtained 
directly from the articles. The outcomes were the maternal 
HBV-DNA levels at delivery and the MTCT rate. The 
different groups of maternal HBV-DNA level were further 
divided into subgroups according to their specific antiviral 
initiation time. MTCT was considered to have occurred if 
HBsAg positivity was observed or if HBV-DNA levels were 
detectable when the infants were seven to 12 months old. 
Then, two analyses were carried out according to subgroups: 
the analysis on the differences in efficacy among various 
antiviral initiation times and the analysis on the differences 
in MTCT rates when HBsAg with respect to HBV-DNA 
seropositivity was used as the outcome.
Risk of bias assessment
The Newcastle-Ottawa Scale (NOS) was used to assess 
the quality of the included observational studies. NOS 
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involves a total of eight items divided into three categories: 
selection (4), comparability (1) and exposure (3). The scale 
ranges from zero to nine points. The studies that met the 
requirements were awarded the corresponding numbers 
of points. A maximum of two stars were given for the 
comparability parameter. A study with a score of more than 
5 points was considered of high quality.
Statistical analysis
We performed the review and meta-analysis according 
to the recommendations of the Cochrane Collaboration. 
To create forest plots, we calculated the risk ratio 
(RR) and 95% confidence interval (95% CI) using a 
binomial distribution for dichotomized outcomes, and 
we determined the weighted mean difference (WMD) 
with 95% CI for continuous outcomes. Before we 
analyzed the data, we tested the heterogeneity among 
the included studies by means of the chi-square test and 
I2 statistic. P<0.05 for the chi-square test or an I2>50% 
were considered as indicative of high heterogeneity. If 
high heterogeneity was observed, a random effect model 
(DerSimonian-Laird method) was used to analyze the 
data. In the absence of significant heterogeneity, a fixed 
model (Mantel-Haenszel method) was applied. When 
considerable heterogeneity was found, a sensitivity 
analysis was performed by omitting one study in each 
iteration to explore the influence of a single study on the 
overall estimate. A P value less than 0.05 was judged 
as statistically significant. All statistical analyses were 
conducted using the Review Manager software, version 
5.3 (Cochrane Collaboration, Copenhagen, Denmark.
RESULTS
The search strategy identified 6,232 papers. After 1,777 
duplicate articles were removed, 4,455 articles remained, 
4,414 of which were excluded on the basis of the title and 
abstract. Then, the full texts of the remaining 41 studies 
were examined. Thirty-two studies were removed: 12 
were related to drug withdrawal; 11 were review articles, 
conference abstracts or reports; seven involved different 
interventions and two reported different outcomes of 
interest. Ultimately, nine studies that met the inclusion 
criteria were included in this meta-analysis.
Characteristics of the included studies
The details of the study selection process are described 
in Figure 1. All the included articles were observational 
cohort studies. The majority of these studies were reported 
in Chinese (n=5)17-21, while four22-25 were reported in 
English. Overall, nine studies that enrolled a total of 
1,502 mothers were included. Most of these studies used 
telbivudine (LdT) and tenofovir disoproxil fumarate (TDF). 
All of the infants were born in China and received active 
and passive combined immunization with 100 IU HBIG 
once in the neonatal period and hepatitis B vaccine three 
times, at zero, one and six months postpartum.
Predelivery maternal HBV-DNA levels (log10 scale) 
after treatment initiation in the second trimester 
compared with the third trimester
All the articles17-25 provided detailed descriptions on the 
maternal HBV-DNA levels before intervention (Table 1). 
There were no statistically significant differences in 
maternal HBV-DNA levels (log10 scale) before treatment 
between mothers who began the antiviral therapy in 
the second trimester and those who began it in the third 
trimester (I2=0%, P=0.25, Table 2). Only six studies18-21,23,25 
reported maternal HBV-DNA levels prior to delivery. 
The pre-delivery maternal HBV-DNA levels (log10 scale) 
differed significantly (P<0.001) between the two groups, 
with distinguished heterogeneity (P<0.001, I2=82%, 
Table 3). Therefore, we performed the subgroups analysis 
according to the different drug treatment initiation times 
(Table 4), which reduced the heterogeneity (I2=0% for 
each subgroup), and evaluated the stability of the results. 
The results indicated that beginning the antiviral therapy in 
the second trimester significantly reduced the HBV-DNA 
levels in HBV-infected mothers (P<0.01 for most subgroup, 
WMD=–0.93, 95% CI -1.08-0.77). 
Thus, compared to the beginning of treatment in the 
third trimester, the onset of antiviral intervention in the 
second trimester distinctly reduced maternal HBV-DNA 
levels, and this effect was related to the antiviral treatment. 
Figure 1 - Flow diagram of the study selection process.
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Table 2 - Antiviral intervention initiated in the second trimester compared to the third trimester in maternal HBV-DNA (log10) before 
treatment.
Study or 
subgroup
Second Trimester Third Trimester
Weight
Mean Difference Mean Difference
Mean SD Total Mean SD Total IV, Fixed, 95% CI IV, Fixed, 95% CI
Han et al.23 7.91 0.75 257 7.83 0.775 105 29.3% 0.08 [-0.09, 0.25]
 
Hu et al.20 8.25 1.22 30 8.13 1.41 30 2.0% 0.12 [-0.55, 0.79]
Liu et al.22 7.67 0.79 24 7.46 0.73 32 8.0% 0.21 [-0.12, 0.54]
Pan et al.25 7.22 0.61 66 7.26 0.55 94 26.2% -0.04 [-0.22, 0.14]
Wang et al.24 7.53 0.81 21 7.53 0.81 27 4.2% 0.00 [-0.46, 0.46]
Wang et al.21 (1) 7.74 1.8 20 7.93 2.06 20 0.6% -0.19 [-1.39, 1.01]
Wang et al.21 (2) 7.74 1.8 20 8.01 1.92 20 0.7% -0.27 [-1.42, 0.88]
Wang et al.21 (3) 7.74 1.8 20 7.47 1.87 20 0.7% 0.27 [-0.87, 1.41]
Wang et al.21 (4) 7.96 2.07 20 7.93 2.06 20 0.5% 0.03 [-1.25, 1.31]
Wang et al.21 (5) 7.96 2.07 20 8.01 1.92 20 0.6% -0.05 [-1.29, 1.19]
Wang et al.21 (6) 7.96 2.07 20 7.47 1.87 20 0.6% 0.49 [-0.73, 1.71]
Wang et al.18 (1) 7.76 1.76 20 7.98 1.9 20 0.7% -0.22 [-1.36, 0.92]
Wang et al.18 (2) 7.76 1.76 20 7.96 1.87 20 0.7% -0.20 [-1.33, 0.93]
Wang et al.18 (3) 7.76 1.76 20 7.4 1.65 20 0.8% 0.36 [-0.70, 1.42]
Wang et al.18 (4) 7.89 1.91 20 7.98 1.9 20 0.6% -0.09 [-1.27, 1.09]
Wang et al.18 (5) 7.89 1.91 20 7.96 1.87 20 0.6% -0.07 [-1.24, 1.10]
Wang et al.18 (6) 7.89 1.91 20 7.4 1.65 20 0.7% 0.49 [-0.62, 1.60]
Yin and Wang19 8.68 1.16 74 8.6 1.26 149 8.0% 0.08 [-0.25, 0.41]
Zhou et al.17 7.52 0.63 49 7.43 0.72 64 14.3% 0.09 [-0.16, 0.34]
Total (95% CI) 761 741 100% 0.06 [-0.04, 0.15]
Heterogeneity: Chi² = 4.67; df = 18 (P = 1.00); I² = 0%
Test for overall effect: Z = 1.15 (P = 0.25)
Table 3 - Antiviral intervention initiated in the second trimester compared to the third trimester in maternal HBV-DNA (log10) prior 
to delivery. 
Study or 
subgroup
Second Trimester Third Trimester
Weight
Mean Difference Mean Difference
Mean SD Total Mean SD Total IV,Randon,95% CI IV,Random,95% CI
Han et al.23 2.5 1.8 257 3.3 1.6 105 7.8% -0.80 [-1.18, -0.42]
 
Hu et al.20 6.3 1.94 30 6.42 2.0 30 5.5% -0.12 [-1.12, 0.88]
Pan et al.25 4.12 1.02 66 4.68 0.9 94 8.0% -0.56 [-0.87, -0.25]
Wang et al.21 (1) 3.38 1.45 20 4.16 1.6 20 5.7% -0.78 [-1.73, 0.17]
Wang et al.21 (2) 3.38 1.45 20 5.45 1.87 20 5.4% -2.07 [-3.11, -1.03]
Wang et al.21 (3) 3.38 1.45 20 5.98 1.67 20 5.6% -2.60 [-3.57, -1.63]
Wang et al.21 (4) 3.68 1.42 20 4.16 1.6 20 5.8% -0.48 [-1.42, 0.46]
Wang et al.21 (5) 3.68 1.42 20 5.45 1.87 20 5.4% -1.77 [-2.80, -0.74]
Wang et al.21 (6) 3.68 1.42 20 5.98 1.67 20 5.7% -2.30 [-3.26, -1.34]
Wang et al.18 (1) 2.97 1.11 20 3.38 1.34 20 6.4% -0.41 [-1.17, 0.35]
Wang et al.18 (2) 2.97 1.11 20 4.83 1.63 20 6.0% -1.86 [-2.72, -1.00]
Wang et al.18 (3) 2.97 1.11 20 5.65 1.45 20 6.3% -2.68 [-3.48, -1.88]
Wang et al.18 (4) 3.22 1.23 20 3.38 1.34 20 6.3% -0.16 [-0.96, 0.64]
Wang et al.18 (5) 3.22 1.23 20 4.83 1.63 20 5.9% -1.61 [-2.50, -0.72]
Wang et al.18 (6) 3.22 1.23 20 5.65 1.45 20 6.2% -2.43 [-3.26, -1.60]
Yin and Wang19 3.57 1.23 74 4.05 1.28 149 7.9% -0.48 [-0.83, -0.13]
Total (95% CI) 667 618 100% -1.27 [-1.67, -0.87]
Heterogeneity: Tau2=0.51; Chi2=85.3; df=15(P<0.00001); I2=82%
Test for overall effect :Z=6.18(P<0.00001)
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Table 4 - Forest plot of antiviral intervention initiated in the second trimester compared to the third trimester with respect to maternal 
HBV-DNA (log10) prior to delivery (subgroups analyses according to different starting times). 
Study or subgroup
Second Trimester Third Trimester
Weight
Mean Difference Mean Difference
Mean SD Total Mean SD Total IV,Fixed,95% CI IV,Fixed,95% CI
4.1 20 w VS 28 w
 
Wang et al.21 (1) 3.38 1.45 20 4.16 1.6 20 2.6% -0.78 [-1.73, 0.17]
Wang et al.18 (1) 2.97 1.11 20 3.38 1.34 20 4.1% -0.41 [-1.17, 0.35]
Subtotal (95% CI) 40 40 6.7% -0.56 [-1.15, 0.04]
Heterogeneity: Chi² = 0.36, df = 1 (P = 0.55); I² = 0%
Test for overall effect: Z = 1.83 (P = 0.07)
4.2 20 w VS 32 w
Wang et al.21 (2) 3.38 1.45 20 5.45 1.87 20 2.2% -2.07 [-3.11, -1.03]
Wang et al.18 (2) 2.97 1.11 20 4.83 1.63 20 3.2% -1.86 [-2.72, -1.00]
Subtotal (95% CI) 40 40 5.4% -1.95 [-2.61, -1.28]
Heterogeneity: Chi² = 0.09, df = 1 (P = 0.76); I² = 0%
Test for overall effect: Z = 5.74 (P < 0.00001)
4.3 20 w VS 36 w
Wang et al.21 (3) 3.38 1.45 20 5.98 1.67 20 2.5% -2.60 [-3.57, -1.63]
Wang et al.18 (3) 2.97 1.11 20 5.65 1.45 20 3.7% -2.68 [-3.48, -1.88]
Subtotal (95% CI) 40 40 6.2% -2.65 [-3.26, -2.03]
Heterogeneity: Chi² = 0.02, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 8.41 (P < 0.00001)
4.4 24 w VS 28 w
Wang et al.21 (4) 3.68 1.42 20 4.16 1.6 20 2.7% -0.48 [-1.42, 0.46]
Wang et al.18 (4) 3.22 1.23 20 3.38 1.34 20 3.7% -0.16 [-0.96, 0.64]
Yin and Wang19 3.57 1.23 74 4.05 1.28 149 19.6% -0.48 [-0.83, -0.13]
Subtotal (95% CI) 114 189 26.1% -0.43 [-0.74, -0.13]
Heterogeneity: Chi² = 0.53, df = 2 (P = 0.77); I² = 0%
Test for overall effect: Z = 2.82 (P = 0.005)
4.5 24 w VS 32 w
Wang et al.21 (5) 3.68 1.42 20 5.45 1.87 20 2.2% -1.77 [-2.80, -0.74]
Wang et al.18 (5) 3.22 1.23 20 4.83 1.63 20 3.0% -1.61 [-2.50, -0.72]
Subtotal (95% CI) 40 40 5.2% -1.68 [-2.35, -1.00]
Heterogeneity: Chi² = 0.05, df = 1 (P = 0.82); I² = 0%
Test for overall effect: Z = 4.87 (P < 0.00001)
4.6 24 w VS 36 w
Wang et al.21 (6) 3.68 1.42 20 5.98 1.67 20 2.6% -2.30 [-3.26, -1.34]
Wang et al.18 (6) 3.22 1.23 20 5.65 1.45 20 3.4% -2.43 [-3.26, -1.60]
Subtotal (95% CI) 40 40 6.0% -2.37 [-3.00, -1.74]
Heterogeneity: Chi² = 0.04, df = 1 (P = 0.84); I² = 0%
Test for overall effect: Z = 7.39 (P < 0.00001)
4.7 the second trimester vs the third trimester
Han et al.23 2.5 1.8 257 3.3 1.6 105 16.7% -0.80 [-1.18, -0.42]
Hu et al.20 6.3 1.94 30 6.42 2.0 30 2.4% -0.12 [-1.12, 0.88]
Pan et al.25 4.12 1.02 66 4.68 0.9 94 25.3% -0.56 [-0.87, -0.25]
Subtotal (95% CI) 353 229 44.4% -0.63 [-0.86, -0.40]
Heterogeneity: Chi² = 1.99; df = 2 (P = 0.37); I² = 0%
Test for overall effect: Z = 5.31 (P < 0.00001)
Total (95% CI) 667 618 100% -0.93 [-1.08, -0.77]
Heterogeneity: Chi² = 85.30; df = 15 (P < 0.00001); I² = 82%
Test for overall effect: Z = 11.81 (P < 0.00001)
Test for subgroup differences: Chi² = 82.22; df = 6 (P < 0.00001) ; I² = 92.7%
Relative risk of mother-to-child transmission with 
antiviral therapy initiation in the second vs. third trimester
Among the 1,502 enrolled pregnant women, 761 began 
to receive antiviral treatment in the second trimester, while 
741 received it in the third trimester. The percentages of 
newborns with HBsAg or HBV-DNA seropositivity in the 
second trimester group and third trimester group were 0% 
Rev Inst Med Trop São Paulo. 2020;62:e13
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Table 5 - Forest plot of HBV MTCT rate (the second trimester or the third trimester).
Study or Subgroup
Second Trimester Third Trimester
Weight
Risk Ratio Risk Ratio
Events Total Events Total M-H,Fixed,95% CI M-H,Fixed,95% CI
Han et al.23 0 257 0 105 Not estimable
 
Hu et al.20 0 30 1 30 17.8% 0.33 [0.01, 7.87]
Liu et al.22 0 24 2 32 25.5% 0.26 [0.01, 5.26]
Pan et al.25 0 66 0 94 Not estimable
Wang et al.24 0 21 0 27 Not estimable
Wang et al.21 (1) 0 20 0 20 Not estimable
Wang et al.21 (2) 0 20 0 20 Not estimable
Wang et al.21 (3) 0 20 0 20 Not estimable
Wang et al.21 (4) 0 20 0 20 Not estimable
Wang et al.21 (5) 0 20 0 20 Not estimable
Wang et al.21 (6) 0 20 0 20 Not estimable
Wang et al.18 (1) 0 20 0 20 Not estimable
Wang et al.18 (2) 0 20 0 20 Not estimable
Wang et al.18 (3) 0 20 0 20 Not estimable
Wang et al.18 (4) 0 20 0 20 Not estimable
Wang et al.18 (5) 0 20 0 20 Not estimable
Wang et al.18 (6) 0 20 0 20 Not estimable
Yin and Wang19 0 74 0 149 Not estimable
Zhou et al.17 0 49 5 64 56.7% 0.12 [0.01, 2.09]
Total (95% CI) 761 741 100% 0.19 [0.03, 1.08]
Total events 0 8
Heterogeneity: Chi² = 0.27; df = 2 (P = 0.87); I² = 0%
Test for overall effect: Z = 1.87 (P = 0.06)
(0/761) and 1.08% (8/741), respectively. The rate of HBV 
MTCT in the second trimester group was similar to the one 
in the third trimester group, with no significant difference 
between the groups (RR=0.19, 95% CI 0.03-1.08, I2=0%, 
P=0.06, Table 5).
To compare the effects of different antiviral drugs 
initiation times on HBV MTCT rates, we divided the data 
into eight subgroups according to the time at which the 
intervention was initiated (Table 6). The results of the 
different subgroups suggested that different durations of 
antiviral treatment led to similar incidences of HBV MTCT 
(P >0.05).
To assess whether HBsAg seropositivity and HBV-DNA 
seropositivity were equivalent endpoints for the evaluation 
of HBV MTCT, we split the data into two subgroups. 
Among the nine included articles, eight papers17-19,21-25 
reported the HBsAg seropositivity of the infants, while 
seven papers17,18,21-25 reported the HBV-DNA seropositivity 
in the infants. In the HBsAg group, the HBV MTCT rates in 
the second trimester and the third trimester were 0% (0/731) 
and 0.98% (7/711), respectively. The rate of HBV MTCT in 
the second trimester was not significantly lower than the one 
in the third trimester (RR=0.16, 95% CI 0.02-1.28, I2=0%, 
P=0.08) (Table 7). In the HBV-DNA seropositivity group, 
the HBV MTCT rates in the second and third trimesters 
were 0% (0/657) and 0.53% (3/562), respectively (Table 7), 
with no significant difference between the trimesters 
(RR=0.19, 95% CI 0.01-3.51, P=0.26). Thus, with regard 
to HBV MTCT prevention, there is no significant difference 
in MTCT rates when HBsAg with respect to HBV-DNA 
seropositivity was used as the outcome.
DISCUSSION
This meta-analysis had two major findings. Firstly, 
compared to the treatment initiated in the third trimester, 
the antiviral intervention initiated in the second trimester 
could distinctly reduce maternal HBV-DNA levels, and 
this effect was closely related to the time of initiation. In 
addition, second-trimester and third-trimester initiations 
of antiviral treatment yielded similar incidences of HBV 
MTCT, irrespective of the initiation time and the different 
studied outcomes. 
Lamivudine, LdT and TDF are equivalent in terms of 
antiviral efficacy6,26. Hence, in our study, their effects were 
merged and directly compared. In addition, intrauterine 
infection can be almost perfectly prevented when the 
HBV-DNA load of the mother is < 104 copies/mL 
Yang et al.
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Table 6 - Forest plot on the rate of mother-to-child hepatitis B virus transmission (subgroup analyses according to different starting times)
Study or Subgroup Second Trimester Third Trimester Weight Risk Ratio Risk RatioEvents Total Events Total M-H,Fixed,95% CI M-H,Fixed,95% CI
6.1 14 w VS 28 w
 
Hu et al.20 0 30 1 30 17.9% 0.33 [0.01, 7.87]
Subtotal (95% CI) 30 30 17.9% 0.33 [0.01, 7.87]
Total events 0 1
Heterogeneity: Not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
6.2 20 w VS 28 W
Zhou et al.17 0 49 5 65 56.5% 0.12 [0.01, 2.12]
Wang et al.21 (1) 0 20 0 20 Not estimable
Wang et al.18 (1) 0 20 0 20 Not estimable
Subtotal (95% CI) 89 105 56.5% 0.12 [0.01, 2.12]
Total events 0 5
Heterogeneity: Not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
6.3 20 w VS 32 w
Wang et al.18 (2) 0 20 0 20 Not estimable
Wang et al.21 (2) 0 20 0 20 Not estimable
Subtotal (95% CI) 40 40 Not estimable
Total events 0 0
Heterogeneity: Not applicable
Test for overall effect: Not applicable
6.4 20 w VS 36 w
Wang et al.21 (3) 0 20 0 20 Not estimable
Wang et al.18 (3) 0 20 0 20 Not estimable
Subtotal (95% CI) 40 40 Not estimable
Total events 0 0
Heterogeneity: Not applicable
Test for overall effect: Not applicable
6.5 24 w VS 28 w
Wang et al.24 0 21 0 27 Not estimable
Yin and Wang19 0 74 0 149 Not estimable
Wang et al.21 (4) 0 20 0 20 Not estimable
Wang et al.18 (4) 0 20 0 20 Not estimable
Subtotal (95% CI) 135 216 Not estimable
Total events 0 0
Heterogeneity: Not applicable
Test for overall effect: Not applicable
6.6 24 w VS 32 w
Wang et al.18 (5) 0 20 0 20 Not estimable
Wang et al.21 (5) 0 20 0 20 Not estimable
Subtotal (95% CI) 40 40 Not estimable
Total events 0 0
Heterogeneity: Not applicable
Test for overall effect: Not applicable
6.7 24 w VS 36 w
Wang et al.18 (6) 0 20 0 20 Not estimable
Wang et al.21 (6) 0 20 0 20 Not estimable
Subtotal (95% CI) 40 40 Not estimable
Total events 0 0
Heterogeneity: Not applicable
Test for overall effect: Not applicable
6.8 the second trimester and the third trimester
Liu et al.22 0 24 2 32 25.7% 0.26 [0.01, 5.26]
Pan et al.25 0 66 0 94 Not estimable
Han et al.23 0 257 0 105 Not estimable
Subtotal (95% CI) 347 231 25.7% 0.26 [0.01, 5.26]
Total events 0 2
Heterogeneity: Not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Total (95% CI) 761 742 100% 0.20 [0.03, 1.09]
Total events 0 8
Heterogeneity: Chi² = 0.26; df = 2 (P = 0.88); I² = 0%
Test for overall effect: Z = 1.86 (P = 0.06)
Test for subgroup differences: Chi² = 0.25; df = 2 (P = 0.88) ; I² = 0%
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Table 7 - Forest plot on the rate of mother-to-child hepatitis B virus transmission (HBsAg seropositivity or HBV-DNA seropositivity). 
Study or Subgroup
Second Trimester Third Trimester
Weight
Risk Ratio Risk Ratio
Events Total Events Total M-H,Fixed,95% CI M-H,Fixed,95% CI
7.1 HBsAg seropositivity
 
4.4.1 HBsAg seropositivity
Han et al.23 0 257 0 105 Not estimable
Liu et al.22 0 24 2 32 21.6% 0.26 [0.01, 5.26]
Pan et al.25 0 66 0 94 Not estimable
Wang et al.24 0 21 0 27 Not estimable
Wang et al.21 (1) 0 20 0 20 Not estimable
Wang et al.21 (2) 0 20 0 20 Not estimable
Wang et al.21 (3) 0 20 0 20 Not estimable
Wang et al.21 (4) 0 20 0 20 Not estimable
Wang et al.21 (5) 0 20 0 20 Not estimable
Wang et al.21 (6) 0 20 0 20 Not estimable
Wang et al.18 (1) 0 20 0 20 Not estimable
Wang et al.18 (2) 0 20 0 20 Not estimable
Wang et al.18 (3) 0 20 0 20 Not estimable
Wang et al.18 (4) 0 20 0 20 Not estimable
Wang et al.18 (5) 0 20 0 20 Not estimable
Wang et al.18 (6) 0 20 0 20 Not estimable
Yin and Wang19 0 74 0 149 Not estimable
Zhou et al.17 0 49 5 64 47.9% 0.12 [0.01, 2.09]
Subtotal (95% CI) 731 711 69.5% 0.16 [0.02, 1.28]
Total events
Heterogeneity: Chi² = 0.15; df = 1 (P = 0.70); I² = 0%
Test for overall effect: Z = 1.73 (P = 0.08)
7.2 HBV DNA seropositivity
Han et al.23 0 257 0 105 Not estimable
Liu et al.22 0 24 0 32 Not estimable
Pan et al.25 0 66 0 94 Not estimable
Wang et al.24 0 21 0 27 Not estimable
Wang et al.21 (1) 0 20 0 20 Not estimable
Wang et al.21 (2) 0 20 0 20 Not estimable
Wang et al.21 (3) 0 20 0 20 Not estimable
Wang et al.21 (4) 0 20 0 20 Not estimable
Wang et al.21 (5) 0 20 0 20 Not estimable
Wang et al.21 (6) 0 20 0 20 Not estimable
Wang et al.18 (1) 0 20 0 20 Not estimable
Wang et al.18 (2) 0 20 0 20 Not estimable
Wang et al.18 (3) 0 20 0 20 Not estimable
Wang et al.18 (4) 0 20 0 20 Not estimable
Wang et al.18 (5) 0 20 0 20 Not estimable
Wang et al.18 (6) 0 20 0 20 Not estimable
Zhou et al.17 0 49 3 64 30.5% 0.19 [0.01, 3.51]
Subtotal (95% CI) 657 562 30.5% 0.19 [0.01, 3.51]
Total events 0 3
Heterogeneity: Not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 1,388 1,273 100% 0.17 [0.03, 0.92]
Total events 0 10
Heterogeneity: Chi² = 0.15; df = 2 (P = 0.93); I² = 0%
Test for overall effect: Z = 2.06 (P = 0.04)
Test for subgroup differences: Chi² = 0.00; df = 1 (P = 0.94) ; I² = 0%
(103 IU/mL)27-29, which is considered a safety maternal 
pre-delivery HBV-DNA threshold for HBV MTCT 
prevention. Among the included studies, the maternal pre-
delivery HBV-DNA levels in mothers that began antiviral 
therapy in the second trimester were approximately 
3 log10 copies/mL18,19,21, while the corresponding 
Yang et al.
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values in the third trimester were approximately 
4 log10 copies/mL18,19,21,25. Both groups were within the 
safety threshold. This finding could explain why the 
antiviral therapy initiated in the second trimester, in 
contrast with the one initiated in the third trimester, could 
significantly reduce the maternal pre-delivery HBV-DNA 
levels without changing MTCT.
However, some results should not be ignored. The 
P value for the difference in HBV MTCT rate between 
the second and the third trimester group was 0.06, which 
was close to the threshold for a statistically significant 
difference (0.05). Furthermore, in the included studies, 
the average maternal HBV- DNA level before treatment 
was approximately 8 log10 copies/mL. In mothers who 
began the antiviral intervention in the third trimester, 
the average maternal HBV- DNA level prior to delivery 
was approximately 4 log10 copies/mL, close to the safety 
threshold for HBV MTCT prevention. These findings 
suggest that the initiation of antiviral treatment can be 
delayed until the third trimester in mothers in whom HBV-
DNA levels are less than or equal to 8 log10 copies/mL. 
This type of treatment with a shorter duration, fewer side 
effects and lower financial burden, will be more suitable 
than second trimester-initiated treatment for the widespread 
use to prevent HBV MTCT. However, if the HBV-DNA 
level in a mother exceeds 8 log10 copies/mL and antiviral 
therapy is initiated in the third trimester, the risk of HBV 
MTCT may increase. Larger sample size cohort studies, 
including subjects with higher maternal HBV-DNA levels 
are needed to verify this hypothesis. 
Recently, two similar meta-analyses compared the 
efficacy of antiviral treatment started in the second trimester 
with the one strated on the third trimester for preventing 
HBV MTCT. In 2014, a study30 reported that antiviral 
intervention is effective in preventing HBV MTCT whether 
it is started in the second or the third trimester, with no 
significant difference in the rate of vertical transmission. 
In 2018, another study6 reported that antiviral intervention 
initiated in the second trimester might be better than the 
one initiated in the third trimester, as indicated by the HBV-
DNA seropositivity rather than the HBsAg seropositivity in 
infants. In the latter study, the time to diagnosis of MTCT 
was within 24 h after delivery, which may have led to an 
overestimation of the MTCT rate30-32. Therefore, in our 
study, MTCT was considered to have occurred if HBsAg 
positivity was observed or if HBV- DNA levels were 
detectable when infants were seven to 12 months old.
This meta-analysis has four advantages. Above all, we 
searched for comprehensive databases, updated the included 
articles and merged the effects of different antiviral drugs. 
Moreover, all the included studies were parallel control 
trials, which have greater power than single-arm studies. 
Most importantly, this study is the first to interpret why 
initiating antiviral therapy in the second trimester rather 
than in the third trimester can distinctly reduce maternal 
pre-delivery HBV-DNA levels without changing MTCT. 
Finally, we divided maternal HBV-DNA levels prior to 
delivery and the HBV MTCT incidences into several 
subgroups according to specific drug intervention times to 
further explore associations of specific treatment durations 
with the examined outcomes.
The present study also has some limitations. Firstly, 
there is a lack of high-quality RCTs and cohort studies with 
larger sample sizes because of ethical restrictions, among 
other reasons. Secondly, different countries have different 
vaccination methods and MTCT diagnostic criteria. To 
improve the comparability, our inclusion criteria limited 
studies carried out with different methods. Thus, even 
though there was no language restriction, all the study 
participants were Asian. These limitations need to be 
considered when evaluating the conclusions.
CONCLUSION
For pregnant women with HBV-DNA levels less than or 
equal to 8 log10 copies/mL initiation of antiviral treatment 
can be delayed until the third trimester of pregnancy.
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